Geoffrey A. Kerchner
A5020503738- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Neuroscience and Neuropharmacology Research
- Parkinson's Disease Mechanisms and Treatments
- Functional Brain Connectivity Studies
- Memory and Neural Mechanisms
- Health Systems, Economic Evaluations, Quality of Life
- Statistical Methods in Clinical Trials
- Neurological disorders and treatments
- Medical Imaging Techniques and Applications
- Ion channel regulation and function
- Advanced Neuroimaging Techniques and Applications
- Cholinesterase and Neurodegenerative Diseases
- Advanced MRI Techniques and Applications
- Pain Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Computational Drug Discovery Methods
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Memory Processes and Influences
- Tryptophan and brain disorders
- Genetic Neurodegenerative Diseases
- S100 Proteins and Annexins
- Nuclear Receptors and Signaling
- Trace Elements in Health
- Brain Tumor Detection and Classification
Roche (Switzerland)
2019-2025
Stanford University
2014-2024
La Roche College
2023-2024
Heinrich Heine University Düsseldorf
2022
Düsseldorf University Hospital
2022
Hertie Institute for Clinical Brain Research
2022
Roche (Sweden)
2022
Vita-Salute San Raffaele University
2020
Istituti di Ricovero e Cura a Carattere Scientifico
2020
VA Palo Alto Health Care System
2012-2014
We used the ratioable fluorescent dye mag-fura-5 to measure intracellular free Zn2+ ([Zn2+]i) in cultured neocortical neurons exposed neurotoxic concentrations of concert with depolarization or glutamate receptor activation and identified four routes entry. Neurons extracellular plus high K+ responded a peak cell body signal corresponding [Zn2+]i 35-45 nM. This increase was attenuated by concurrent addition Gd3+, verapamil, omega-conotoxin GVIA, nimodipine, consistent entry through...
Significance Circulating cell-free RNA in the blood provides a potential window into health, phenotype, and developmental programs of variety human organs. We used high-throughput methods analysis such as microarrays next-generation sequencing to characterize global landscape circulating subjects. By focusing on tissue-specific genes, we were able identify relative contributions these tissues monitor changes during tissue development neurodegenerative disease states.
Aggregated α-synuclein plays an important role in the pathogenesis of Parkinson’s disease. The monoclonal antibody prasinezumab, directed at aggregated α-synuclein, is being studied for its effect on
Cognitive processing slows with age. We sought to determine the importance of white matter integrity, assessed by diffusion tensor imaging (DTI), at influencing cognitive speed among normal older adults, using a novel battery computerized, non-verbal, choice reaction time tasks. studied 131 cognitively adults aged 55–87 cross-sectional design. Each participant underwent our test battery, as well MRI DTI. carried out cross-subject comparisons tract-based spatial statistics. As expected,...
Abstract Background We previously investigated low doses (105 or 225 mg) of gantenerumab, a fully human monoclonal antibody that binds and removes aggregated amyloid-β by Fc receptor-mediated phagocytosis, in the SCarlet RoAD (SR) Marguerite (MR) phase 3 trials. Several lines evidence suggested higher may be necessary to achieve clinical efficacy. therefore designed positron emission tomography (PET) substudy evaluate effect gantenerumab uptitrated 1200 mg every 4 weeks on plaques as...
<h3>Importance</h3> Neurofibrillary tangles composed of aggregated tau protein are one the neuropathological hallmarks Alzheimer disease (AD) and correlate with clinical severity. Monoclonal antibodies targeting may have potential to ameliorate AD progression by slowing or stopping spread and/or accumulation pathological tau. <h3>Objective</h3> To evaluate safety efficacy monoclonal anti-tau antibody semorinemab in prodromal mild AD. <h3>Design, Setting, Participants</h3> This phase 2...
Abstract Prasinezumab, a monoclonal antibody that binds aggregated α-synuclein, is being investigated as potential disease-modifying therapy in early-stage Parkinson’s disease. Although the PASADENA phase 2 study, primary endpoint (Movement Disorder Society Unified Disease Rating Scale (MDS-UPDRS) sum of Parts I + II III) was not met, prasinezumab-treated individuals exhibited slower progression motor signs than placebo-treated participants (MDS-UPDRS Part III). We report here an exploratory...
Abstract Parkinson’s disease (PD) starts at the molecular and cellular level long before motor symptoms appear, yet there are no early-stage biomarkers for diagnosis, prognosis prediction, or monitoring therapeutic response. This lack of greatly impedes patient care translational research— l -DOPA remains standard more than 50 years after its introduction. Here, we performed a large-scale, multi-tissue, multi-platform proteomics study to identify new early diagnosis in PD. We analyzed 4877...
<h3>Objectives:</h3> In Alzheimer disease (AD), mounting evidence points to a greater role for synaptic loss than neuronal loss. Supporting this notion, multiple postmortem studies have demonstrated that the hippocampal CA1 apical neuropil is one of earliest sites pathology, exhibiting tau aggregates and then atrophy before there substantial pyramidal neurons themselves. cross-sectional study, we tested whether tissue in layer can be observed vivo patients with mild AD. <h3>Methods:</h3> We...
The advent of high-resolution magnetic resonance imaging (MRI) has enabled in vivo research a variety populations and diseases on the structure function hippocampal subfields subdivisions parahippocampal gyrus. Because many extant highly discrepant segmentation protocols, comparing results across studies is difficult. To overcome this barrier, Hippocampal Subfields Group was formed as an international collaboration with aim developing harmonized protocol for manual subregions MRI. In...
<h3>Importance</h3> Young mouse plasma restores memory in aged mice, but, to our knowledge, the effects are unknown patients with Alzheimer disease (AD). <h3>Objective</h3> To assess safety, tolerability, and feasibility of infusions young fresh frozen (yFFP) from donors age 18 30 years AD. <h3>Design, Setting, Participants</h3> The Plasma for Symptom Amelioration (PLASMA) study randomized 9 under a double-blind crossover protocol receive 4 once-weekly either 1 unit (approximately 250 mL)...
Abstract To date, there is no validated fluid biomarker for tau pathology in Alzheimer’s disease, with contradictory results from studies evaluating the correlation between phosphorylated CSF PET imaging. Tau protein subjected to proteolytic processing into fragments before being secreted CSF. A recent study suggested that cleavage after amino acid 368 by asparagine endopeptidase (AEP) upregulated disease. We used immunoprecipitation followed mass spectrometric analyses evaluate presence of...
Semorinemab shows beneficial effects in preclinical models and engages tau a phase 1 study of patients with Alzheimer’s disease.
Small diameter dorsal root ganglion (DRG) neurons, which include cells that transmit nociceptive information into the spinal cord, are known to express functional kainate receptors. It is well established exposure will depolarize C-fiber afferents arising from these cells. Although role of receptors on sensory unknown, it has been hypothesized presynaptic may regulate glutamate release in cord. Here we show kainate, applied at low micromolar concentrations presence AMPA-selective antagonist...